Recall Register

Device recall: VITEK 2 Gram-negative Susceptibility Cards Containing o Polymyxin B (pb02n) o Ceftazidime/avibactam (cza02n) o…

Class II FDA enforcement event 98268. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Potential risk of Quality Control failures and/or false resistant antibiotic results when testing isolates of Enterobacterales/Enterobacteriaceae species and/or Pseudomonas aeruginosa with the identified antibiotic formulations. Issue may lead to QC failure or false resistant results.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Biomerieux Inc started this device recall on 5 Jan 2026. The firm address in the FDA record is in Hazelwood, MO. FDA put the recall in Class II. FDA event 98268 has 1 product record. The first FDA enforcement report date is 11 Feb 2026. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Worldwide - US Nationwide distribution.

Recalling firm

Biomerieux Inc, Hazelwood, MO.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 98268: product records
Recall numberProductQuantityClassStatusReport date
Z-1236-2026VITEK 2 Gram-negative Susceptibility Cards Containing o Polymyxin B (pb02n) o Ceftazidime/avibactam (cza02n) o Meropenem/Vaborbactam (mev01n) o Imipenem (ipm05n) o Imipenem/Relebactam (ipr01n); CARD NAME/ PRODUCT REFERENCE: AST-N399 423701 AST-N402 423644 AST-N403 423645 AST-N404 423664 AST-N405 423864 AST-N406…2,668,954 totalClass IIOngoing11 Feb 2026

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Device events that started in 2026
572
Share of these events in Class II
87%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
57

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 98268. https://recallregister.com/fda/ii/98268/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA device enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Worldwide - US Nationwide distribution.
What quantity of product is in FDA event 98268?
The FDA record gives this quantity: 2,668,954 total
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many device recalls of 2026 have the same class?
87% of the 572 device events that started in 2026 are in Class II.